Rafiq Hasan, Complement Therapeutics CEO
VCs 'Complement' European biotech with $79M for retinal AAV gene therapy trial next year
Complement Therapeutics raised a €72 million ($79.6 million) Series A to bankroll a Phase Ib of its AAV gene therapy in geographic atrophy.
The disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
